The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting

Stephen F. Hall MSc, MD, FRCSC1 | Rebecca J. Griffiths BSc2 |
Brian O’Sullivan MB BCh, BAO, FRCPC3 | Fei-Fei Liu MD, FRCPC3

1Department of Otolaryngology and Division of Cancer Care and Epidemiology of the Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada
2Cancer Care and Epidemiology at the Queen’s Cancer Research Institute, Queen’s University, Kingston, Ontario, Canada
3Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada

Correspondence
Stephen F. Hall, Department of Otolaryngology and Division of Cancer Care and Epidemiology of the Queen’s Cancer Research Institute, Queen’s University, 10 Stuart St, Kingston K7L 4N6, Ontario, Canada.
Email: sfh@queensu.ca

Funding information
The Canadian Institutes of Health Research, Grant/Award Number: 111231; Canadian Cancer Society Research Institute, Grant/Award Number: #210554; Canadian Institutes of Health Research, Grant/Award Numbers: #111231, #210554.

Abstract

Background: Distant metastases (DM) are a leading cause of death for patients with oropharyngeal cancer (OPSCC). The objective of this study was to compare the rates of DM after chemoradiotherapy (CRT) and radiotherapy alone (RT) in patients with human papillomavirus (HPV)-positive and HPV-negative OPSCC.

Method: In a retrospective population-based study of 525 patients across Ontario, Canada, in 1998/99/03/04, we compared treatment effectiveness using cumulative incidence function curves and cause-specific Cox regression models.

Results: Sixty of 525 patients developed DM. There was no difference in rates (overall 10%-15%) between HPV-positive and HPV-negative patients or between CRT- and RT-treated patients. CRT reduced the risk of DM for the 15% of all HPV-positive patients with higher risk (T4 and/or N3) and not for HPV-negative patients (hazard ratio, 1.82 [0.65-5.07]).

Conclusion: The addition of platin-based chemotherapy to conventional RT did not decrease the rates of DM in the majority of patients with HPV-positive or in HPV-negative OPSCC.

KEYWORDS
chemoradiotherapy, distant metastases, HPV status, oropharynx, population-based

INTRODUCTION

In the early 2000s, the standard of care for many patients with squamous cell carcinoma of the head and neck, including oropharynx, evolved from radiotherapy (RT) to chemoradiotherapy (CRT) based on clinical trials (including Calais et al.,1 Denis et al.,2 Jeremic et al.,3 Wendt et al.4), meta-analyses (Pignon et al.,5 Bourhis et al.6), systematic reviews (Browman et al.,7 Hao et al.8), and clinical practice guidelines9 that reported improved survival and improved local-regional control. Subsequent meta-analyses have supported that evidence,10–12 but there is little information on the impact of concurrent CRT specifically on the rate of distant metastases (DM). The only supporting evidence is a 2.5% improvement in 5-year DM (hazard ratio [HR], 0.88; P = 0.04) reported by Pignon et al. in 200911 that was based on 93 trials with heterogeneous patient populations, chemotherapy protocols, and RT regimens. The GORTEC trial13 that compared platin-based concurrent CRT to conventional RT for oropharyngeal cancer (OPSCC) patients did not find a difference in DM. Some studies report crude proportions of DM without adjusting for competing risk and most do not...
have sufficient events to investigate prognostic factors. All the studies, however, predated our knowledge about and testing for human papillomavirus (HPV) leading Mroz14 to conclude that the “interpretation of these studies might have been misled by what we now know to have been the substantially different tumor biology of the undetermined numbers of patients with HPV+ve OPSCC.” More recently, O'Sullivan et al.15 found similar rates of DM comparing HPV-positive with HPV-negative OPSCC patients and reported that the impact of risk factors such as N Category and T Category varied between HPV-positive and HPV-negative patients. They suggested cautiously that lower risk patients could be candidates to withhold or reduce chemotherapy. Similarly, other authors have found no difference in the rates of DM between HPV-positive and HPV-negative patients.16,17 although there appears to be differences in time to DM15,16,18 and in locations of DM18–20 when comparing HPV-positive with HPV-negative patients.

DM is a leading cause of death in HPV-positive OPSCC, yet our understanding of the true impact of the addition of chemotherapy to RT on DM for HPV-positive or HPV-negative OPSCC is essentially not known. The objective of this study was to compare the rate of DM in patients with OPSCC treated with concurrent CRT vs conventional RT alone in a population-based data set of unselected real-world patients. The study is based on data from a previously published unique observational population-based real-world study21 that compared patients, treatments, and outcomes from across the Province of Ontario, Canada, in the prechemotherapy era of 1998/99 to the initial postchemotherapy era of 2003/04.

2 | METHOD

This is a retrospective cohort study based on 610 patients with OPSCC diagnosed between January 1, 1998 and December 31, 1999 and between January 1, 2003, and December 31, 2004, who were treated for cure with either RT or CRT and on whom we could obtain tissue and HPV status via external laboratory blinded testing using either p16 or both p16 and in situ hybridization. The patient identification, chart abstraction, data collection, variables, patient data, treatment details, HPV testing protocols, HPV results, causes of death, and survival outcomes are described in previous publications.21–23 Staging was based on TNM sixth edition. Of the 610 patients, 243 were from the 98/99 cohort, 199 were treated with CRT and 392 were HPV-positive. Only 3 of the 610 had known HPV status at the time of treatment. The data abstraction included up to second relapse after a disease-free statement on the chart following initial treatment. In the absence of consistent and reliable information on smoking on the patient charts, smoking status was estimated using the Cumulative Illness Rating Scale24 based on information on the charts. The Cumulative Illness Rating Scale is a 13-domain summative predictive index of comorbidity and its 5-level respiratory domains closely align to severity of chronic obstructive pulmonary disease. “Never” smokers were recorded as 0 and patients with respiratory failure were recorded as 4. To estimate smoking levels, we reduced the 5 levels to 2 (0-1, >1) that would reflect no or light smoking vs heavier smoking.

The study population is 525 of the 610 patients who were declared disease-free at the end of curative initial treatment with either RT or CRT. Disease status decisions were made and recorded by the attending oncologists and/or the tumor board at routine follow-up based on the clinical, radiological and follow-up protocols of each cancer treatment center. Residual disease and recurrent disease were distinguished based on the presence or absence of a disease-free status statement on the chart. Curative initial treatment for this study included the treatment of residual disease as that would be assumed to be part of initial planned treatment. Overall, 54 patients were treated with daily cisplatin, 22 with weekly cisplatin, 87 with cisplatin q3weeks, 25 with carboplatin (22 on weekly regimen), and 11 with a combination of either cisplatin or carboplatin with 5FU. Cetuximab was not used during 2003/04 in Ontario. The outcomes were site of first recurrence and any DM (first or second recurrence). The mean follow-up time was 68.2 months from diagnosis. We report the proportions of DMs by HPV status and treatment. Logistic regression (DM yes/no) was used to investigate prognostic factors for any DM controlling for treatment, HPV status, T Category, and N Category. The baseline group was CRT, HPV-negative, T1, and N0. Six patients who were lost to follow-up were excluded noting that their mean follow-up was 45.2 months. To account for the competing risks of death and first recurrence, we used Gray’s test for equality of cumulative incidence functions to compare rates of DM by treatment for the HPV-positive and HPV-negative cohorts.25 We included first recurrence to the primary or neck as a competing risk as second treatment might influence rates of metastases. The comparison of Cumulative Incidence Function (CIF) curves was based on chi-squared test and the P-value was reported. Cause-specific Cox regression models26–28 were generated to compare risk factors including treatment for DM. The baseline variables included age (50-59 years), male sex, comorbidity (ACE-27 = 029), T1 Category, N0 Category, subsite = tonsil, treatment = CRT, HPV-positive, light smoking, and low risk of DM.

Patients were grouped into high and low “risk of DM” based on combinations T and N Category as per O'Sullivan et al.15 They defined the high-risk group for HPV-positive patients as T4 and/or N3 and for the HPV-negative patients as T3-4 and/or N3. The risk of DM was compared in our study by group including the treatment and smoking status variables.

3 | RESULTS

One hundred twenty-five of the 525 patients recurred and the sites of first recurrence are outlined on Figure 1A,B.
Eventually, 60 patients developed DM, of which 36 were isolated DM. The study population including HPV status and rates of any DM are presented in Table 1. DM occurred in 9.6% of the HPV-positive and 15.0% of HPV-negative patients (P-value 0.07). DM occurred in 10.8% of the RT and 12.5% of the CRT patients. Overall, 200 patients died of their oropharynx, including 143 of the RT-treated and 57 of the CRT group. One hundred eight patients died of other causes (89 RT, 19 CRT).

The risk factors for the development of DM based on all patients using logistic regression were N3 (OR 5.03 [1.14-22.23]) and HPV-negative status (OR = 1.94 [1.07-3.52]) (data not included). The addition of chemotherapy did not have a statistically significant impact on the risk of DM (OR 1.06 [0.57-1.98] over RT alone. Similarly for the HPV-positive cohort only, the addition of chemotherapy to RT alone did not have a significant impact (OR 0.89 [0.41-1.92]) over RT alone similar to the results for the HPV-negative cohort (OR 1.37 [0.45-4.15]).

The CIF curves comparing CRT to RT for the HPV-positive and HPV-negative patients are presented in Figure 2A,B. There was no statistically significant difference in rates of DM with the use of CRT for either cohort (P = 0.34, P = 0.77). Similar results were obtained when the CIF curves only accounted for death as a competing risk (P = 0.41, P = 0.85).

The results of the cause-specific hazards model for all patients are presented in Table 2. Age, sex, comorbidity, and subsite were not significant and are not included in the table. The risk factors for the development of DM were T3, N2, N3, and HPV-negative status. The addition of CRT was not significant (HR, 1.15 [0.64-2.07]). When the analysis was performed for the HPV-positive cohort (Table 3), the only statistically significant factor was T4 (HR, 4.12 [1.17-14.57]) with only a trend toward significance in the very small number of N3 cases in the study (n = 17). For the HPV-negative patients, the risk factor was N2 (HR, 6.78 [2.197-20.94]) and CRT had no statistically significant impact (HR, 1.82 [0.65-5.07]). Treatment, that is, CRT, did not influence the rates of DM for the HPV-positive and HPV-negative patients. Similar results were obtained when accounting for death only as a competing risk in the models.

Table 4 presents the model for high and low “risk of DM” groups for the HPV-positive cohort. The high-risk group did develop more DM (HR = 2.80, 1.27-6.17, P = 0.01). Smoking status was not a statistically significant factor. The model for the HPV-negative cohort showed similar nonstatistically significant results for treatment and smoking, and high “risk of DM” group was not statistically significantly different (HR = 1.55, 0.69-3.5).

4 | DISCUSSION

The objective of this study was to determine, in the absence of evidence, the impact of the addition of concurrent

---

**TABLE 1** Patient, tumor, and treatment characteristics and the rates of DM for 525 patients by HPV status

| Variable       | HPV-positive | HPV-negative |
|----------------|--------------|--------------|
|                | No. of patients | No. of patients with DM | No. of patients | No. of patients with DM |
| Sex            | Male 279 27 117 18 | Female 73 7 56 8 |
| Smoking        | Light 218 20 37 5 | Heavy 134 14 136 21 |
| T Category     | T1 102 6 29 4 | T2 148 14 83 10 | T3 64 8 33 7 | T4 38 6 28 5 |
| N Category     | N0 64 8 76 5 | N1 65 2 34 5 | N2 209 21 62 16 | N3 14 3 1 0 |
| Subsite        | Base of tongue 116 12 49 11 | Tonsil/palate 236 22 124 15 |
| Risk group     | High 52 9 62 12 | Low 300 25 111 14 |
| Treatment      | RT 215 19 140 20 | CRT 137 15 33 6 |
| Total          | 352 34 173 26 |

Abbreviations: CRT, chemoradiotherapy; DM, distant metastases; RT, radiotherapy alone.
chemotherapy to conventional RT for patients with HPV-positive and HPV-negative patients with OPSCC specifically on the rates of DM. Based on 525 patients who were declared disease-free after curative treatment and 60 developed DM. Between 10% and 15% of patients developed DM regardless of HPV status and treatment. CRT did not influence the rate overall, for the HPV-positive cohort or for the HPV-negative cohort. In the most recent meta-analysis comparing CRT to RT alone, Blanchard et al.\textsuperscript{10} reported a 5-year benefit in overall survival of 8.1% (HR, 7.8) for OPSCC patients and given this advantage compared to rates of toxicity and cost, the lack of impact on DM should be of interest to patients, oncologists, funders and policy makers. The decision use CRT for any patient needs to consider all the evidence including overall survival, local control, regional control, DM, and toxicity.

Our results are consistent with those of O'Sullivan\textsuperscript{15} who reported no difference in the rates of DM between HPV-positive and HPV-negative OPSCC. They identified different risk strata for development of DM based on combinations of T and N Category for each HPV status group. Our results support their risk strata for the HPV-positive patients as patients with T4 and/or N3 disease had fewer DM events and strongly endorse their conclusion “that lower risk patients could be candidates to withhold or reduce chemotherapy” noting that this group only represents 52/352 (14.7%) of all HPV-positive cases. For the HPV-negative patients, we found that overall the risk of DM was greater than the HPV-positive patients (Table 2), that the addition of CRT did not reduce the rates of DM overall and we could not identify a higher “risk of DM” group.

The strengths of this study are the inclusion of the complete cohort of “real-world” patients from all treatment centers in Ontario, Canada, in a time when oncologists were...

TABLE 2 The hazards ratios from the cause-specific hazard model for distant metastases based on all patients

| Variable | Hazards ratio | Lower CI | Upper CI | P  |
|----------|---------------|----------|----------|----|
| T Category |               |          |          |    |
| T1       | 1.00          |          |          |    |
| T2       | 1.784         | 0.787    | 4.044    | .1659 |
| T3       | 2.898         | 1.169    | 7.179    | .0216 |
| T4       | 2.469         | 0.929    | 6.560    | .0698 |
| N Category |             |          |          |    |
| N0       | 1.00          |          |          |    |
| N1       | 1.030         | 0.368    | 2.885    | .9544 |
| N2       | 2.651         | 1.248    | 5.630    | .0112 |
| N3       | 7.949         | 1.989    | 31.776   | .0034 |
| Treatment |              |          |          |    |
| CRT      | 1.00          |          |          |    |
| RT       | **1.152**     | **0.641** | **2.070** | **.6363** |
| HPV status |            |          |          |    |
| Negative | 1.00          |          |          |    |
| Positive | 0.357         | 0.197    | 0.647    | .0007 |

Abbreviations: CRT, chemoradiotherapy; RT, radiotherapy alone.

FIGURE 2 A, Cumulative incidence function curve for distant metastasis by treatment for 352 HPV-positive patients. B, Cumulative incidence of distant metastasis by treatment for 173 HPV-negative patients. (RT = radiotherapy alone, CRT = chemoradiotherapy) [Color figure can be viewed at wileyonlinelibrary.com]

TABLE 3 The hazards ratio from the cause-specific hazard model for distant metastases based on the HPV-positive patients

| Variable | Hazards ratio | Lower CI | Upper CI | P  |
|----------|---------------|----------|----------|----|
| T Category |               |          |          |    |
| T1       | 1.00          |          |          |    |
| T2       | 1.852         | 0.644    | 5.327    | .2530 |
| T3       | 2.402         | 0.696    | 8.298    | .1658 |
| T4       | 4.121         | 1.166    | 14.567   | .0280 |
| N Category |             |          |          |    |
| N0       | 1.00          |          |          |    |
| N1       | 0.191         | 0.023    | 1.613    | .1285 |
| N2       | 0.993         | 0.387    | 2.551    | .9891 |
| N3       | 3.654         | 0.833    | 16.034   | .0859 |
| Treatment |              |          |          |    |
| CRT      | 1.00          |          |          |    |
| RT       | **0.894**     | **0.423** | **1.891** | **.7697** |
| HPV status |            |          |          |    |
| Negative | 1.00          |          |          |    |
| Positive | 0.357         | 0.197    | 0.647    | .0007 |

Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; RT, radiotherapy alone.
TABLE 4 The hazard ratios from the cause-specific hazard model for the risk of distant metastases including the variable “distant metastases risk group” and based on the HPV-positive patients

| Variable | Hazards ratio | Upper CI | Lower CI | P     |
|----------|---------------|----------|----------|-------|
| Treatment |               |          |          |       |
| CRT      | 1.00          |          |          |       |
| RT       | 0.826         | 0.399    | 1.709    | .6058 |
| Smoking  |               |          |          |       |
| Light    | 1.00          |          |          |       |
| Heavy    | 1.118         | 0.529    | 2.360    | .7702 |
| Risk group |             |          |          |       |
| Low      | 1.00          |          |          |       |
| High     | 2.800         | 1.271    | 6.171    | .0106 |

Abbreviations: CI, confidence interval; CRT, chemoradiotherapy; RT, radiotherapy alone.

HPV naive. For this study we used competing risk analysis. Other strengths include the unique design that used similar patients from different eras with different rates of HPV-positive, the systematic data collection and quality of the HPV tissue testing. Testing was done at one independent laboratory (the Molecular Oncology Lab, the Princess Margaret Hospital, Toronto, Canada) that was blind to patient identifiers, treatments, and results.

The limitations of the overall study are carefully described in the original publications.21–23 This is not the analysis of a clinical trial but is a meticulously performed retrospective population-based observational study. Booth et al.30–32 have reviewed the “pros and cons” of RCTs compared to population-based studies and concluded that “well-designed population-based outcome studies should be considered a natural step in the evolution of evidence and should be conducted in follow-up of all major randomized controlled trials... due to the fundamental difference between efficacy and effectiveness inherent in the patient selection bias, treatment bias and settings of RCTs that differ from practice in the community.” Studies such as ours can be used to support or question controversial or confusing findings. There is no other study that compares DM in HPV-positive and HPV-negative patients comparing conventional RT alone to CRT.

There are six potential limitations for this substudy. First, we unfortunately did not abstract the location of the DM. This would be of particular interest, given reports of differences in DM sites.18–20 Second, it is possible that our results reflect differences in the effectiveness of various chemotherapy regimens used at the time; however, there is no evidence to support this hypothesis either for survival or specifically for DM. Third, in this study of real-world patients it is possible that differences in chemotherapy protocol completion might have affected rates of DM. There is no past evidence suggesting that reducing the total dose of chemotherapy alters the risk of DM and we have not accounted for treatment completion in the analysis. Fourth, as this study is based on treatments and salvage treatments in 1998–2004, it is possible that we have underestimated the current rates of DM as presently more patients might survive salvage treatment only to develop DM. Differences in treatment effectiveness and imaging quality, however, would affect both the HPV-positive and HPV-negative cohorts and both treatment cohorts. Differences in imaging in 1998/98 are irrelevant as DM would eventually appear and there is no evidence of a curative treatment for DM in this condition. Fifth, we did not consider time to DM. O’Sullivan,15 Huang,16 and Trosman18 all reported that HPV-negative patients develop DM sooner than HPV-positive patients and our Figure 2A,B are consistent with the findings of those authors. Finally, we did not find a relationship between smoking and DM as previously reported.15,33 We used a surrogate for smoking based on patient chart information and thus may have underestimated smoking status effect.

5 CONCLUSION

Based on 525 patients with OPSCC treated for cure with either RT or CRT who were declared disease-free at the end of treatment, we found no overall difference in the rates of DM comparing CRT with RT alone for HPV-positive or HPV-negative patients. HPV+ patients with the most advanced disease might benefit, but 90% of OPSCC patients regardless of HPV status need to be informed that there is no evidence for a reduction in DM with addition of platin-based concurrent chemotherapy to conventional RT.

ACKNOWLEDGMENTS

This project was funded by the Canadian Institutes of Health Research (operating grants #111231, #210554) and Canadian Cancer Society Research Institute (operating grant #19174). The project was approved by the Research Ethics Boards of Queen’s University (OTL-028-06), the Princess Margaret Hospital (11-0533-T) and by all Ontario cancer treatment center host hospitals. The use of the data was approved by both the Ontario Cancer Registry and Cancer Care Ontario. The clinical study and analysis was performed at the Division of Cancer Care and Epidemiology, Queen’s Cancer Research Institute, Kingston, Ontario. The joint study coordinators were Tina Dyer and Susan Rohland with assistant Sarah Pickett. The HPV tissue testing was performed by Willa Shi MD, MSc, Department of Medical Biophysics, Ontario Cancer Institute, 610 University Ave Toronto, Canada. M5G 2M9. Presented at the meeting of the Canadian Otolaryngology Society, Quebec City, June 2018.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to report.

AUTHOR CONTRIBUTIONS

Dr Hall and Ms Griffiths were involved throughout the study design, data analysis, manuscript writing and manuscript...
12. Lohaus F, Linge A, Tinhofer I, et al. HPV16 DNA status is a strong prog-
16. 11.
13.
14.
10.
9.
8.
7.
6.
5.
4.
3.
2.
1.
16.
15.
14.
13.
12.
11.
10.
9.
8.
7.
6.
5.
4.
3.
2.
1.
11.
10.
9.
8.
7.
6.
5.
4.
3.
2.
1.
10.
9.
8.
7.
6.
5.
4.
3.
2.
11.
10.
9.
8.
7.
6.
5.
4.
3.
2.
1.
references. Dr Hall had full access to all the clinical data in the study and takes responsibility for the integrity of the clinical data and the accuracy of the data analysis.

**ORCID**

Stephen F. Hall https://orcid.org/0000-0001-8399-7552

**REFERENCES**

1. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiotherapy vs concomitant chemotherapy with radiation therapy for advanced-stage oropharynx cancer. *J Natl Cancer Inst*. 1999;91:2081-2086.
2. Denis F, Garand P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized Trial comparing radiotherapy alone with concomitant radiotherapy in advanced stage oropharynx carcinoma. *J Clin Oncol*. 2004;22:69-76.
3. Jeremic B, Shibamoto Y. Radiation therapy alone or with concurrent low-dose daily cisplatin in locally advanced resectable squamous cell carcin-
oma of the Head and Neck. *Radiat Oncol*. 1997;43:29-37.
4. Wendt T, Grabenauer G, Rodel C, et al. Simultaneous radiochemotherapy vs radiotherapy alone in head and neck cancer. *J Clin Oncol*. 1998;16:1318-1324.
5. Pignon JP, Bourhis J, Domenegge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. *Lancet*. 2000;355:949-955.
6. Bourhis J, Amand C, Pignon J-P. Update of MACH-NC (Meta-analysis of chemotherapy in head and neck cancer): database focused on concomitant chemoradiotherapy. *Proc Am Soc Clin Oncol*. 2004;23:489S.
7. Brownman G, Hudson I, Mackenzie R, Bestic N, Zuraw L. Cancer Care Ontario Practice Guideline Initiative. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the literature with subgroup analysis. *Head Neck*. 2001;23:579-589.
8. Hao D, Ritter M, Oliver T, Brownman G. Platinum based concurrent chemother-
adotherapy for tumors of the head and neck and esophagus. *Semin Radiat Oncol*. 2005;16:10-19.
9. Ontario Provincial Disease Site Group. Cancer care ontario treatment guide-
lines initiative: concomitant chemotherapy and radiotherapy in squamous cell head and neck cancer. 2002. Report No.: #5-6a.
10. Blanchard P, Bajuat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumor site. *Radiother Oncol*. 2011;100(1):33-40.
11. Pignon J-P, le Maire A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized tri-
als and 17,346 patients. *Radiat Oncol*. 2009;92:4-14.
12. Pignon J, le Maire M, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. *Int J Radiat Oncol Biol Phys*. 2007;69:S112-S114.
13. Fallai C, Bolner A, Signor M, et al. Long term results of conventional radio-
therapy vs accelerated hyperfractionated radiotherapy vs concomitant radio-
therapy and chemotherapy on locoregionally advanced carcinoma of the oropharynx. *Tumori*. 2006;92:41-54.
14. Mroz E, Forasteire A, Rocco J. Implications of the oropharyngeal cancer epi-
demic. *J Clin Oncol*. 2011;29:4222-4223.
15. O'Sullivan B, Huang S, Liu L, et al. Deintensification candidate subgroups in human-papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. *J Clin Oncol*. 2013;31:543-550.
16. Huang S, Perez-Ordonez B, Hope A, et al. Natural course of distant meta-
stases following radiotherapy or chemoradiotherapy in HPV-related oropharyn-
geal cancer. *Oncol Rep*. 2013;29:79-85.
17. Lohaus F, Linge A, Tinhofer I, et al. HPV16 DNA status is a strong prog-
osticator of loco-regional control after postoperative radiochemotherapy of
locally advanced oropharyngeal carcinoma. *Radiother Oncol*. 2014;113:
317-323.
18. Trosman S, Koyfman S, Ward M, et al. Effect of human papillomavirus on pat-
terns of distant metastastic failure in oropharyngeal squamous cell carcinoma
with chemoradiotherapy. *JAMA Otolaryngol Head Neck Surg*. 2015;
141:457-462.
19. Huang S, Perez-Ordonez B, Liu F, et al. Atypical behaviour of p16-confirmed
HPV-related oropharyngeal squamous cell carcinoma treated with radio-
therapy. *Int J Radiat Oncol Biol Phys*. 2012;82:276-283.
20. Jaber J, Murrill L, Johnson J, Feustel P, Mehta V. Robust differences in
p16-dependent oropharyngeal squamous cell carcinoma distant metastases:
implications for targeted therapy. *Otolaryngol Head Neck Surg*. 2015;153:
209-217.
21. Hall S, Liu F-F, O'Sullivan B, et al. Did the addition of concurrent chemo-
therapy to conventional radiotherapy improve outcomes for patients with
HPV+ve and HPV-ve oropharynx cancer? *Br J Cancer*. 2017;117:1105-
1112. https://doi.org/10.1038/bjc.2017.275.
22. Hall S, Irish J, Gregg R, Groome P, Rohland S. Adherence to and uptake
of clinical practice guidelines: lessons learned from a clinical practice guideline
on chemotherapy concomitant with radiotherapy in head-and-neck cancer. *Cancer*. 2015;22:651-668. https://doi.org/10.3747/co.22.2235.
23. Hall SF, O'Sullivan BO, Irish J, Gregg R, Meyer R, Groome PA. The impact
of the addition of chemotherapy to radiotherapy for cancer of the oropharynx
in 2003/4: a population-based study from the Province of Ontario Canada.
*Head Neck*. 2015;37:1461-1469.
24. Linn BS, Linn MW, Lee G. Cumulative illness rating scale. *J Am Geriatr
Soc*. 1968;16(5):622-626.
25. Gray R. A class of K-sample tests for comparing the cumulative incidence
of a competing risk. *Ann Stat*. 1988;16:1141-1154.
26. Austin P, Lees D, Fine J. Introduction to the analysis of survival data in the
presence of competing risks. *Circulation*. 2016;133:601-609.
27. Pintilie M. Analyzing and interpreting competing risk data. *Stat Med*. 2007;26:1360-1367.
28. So Y, Lin G, Johnson G. Using the PHREG procedure to analyze
competing-risks data. 2015. The SAS Institute, Cary, NC. Report No.: Paper
SAS1855-2015.
29. Piccirillo JF, Tierney R, Costas I, Grove L, Spitznagel E. Prognostic impor-
tance of comorbidity in a hospital based cancer registry. *JAMA*. 2004;291:
2441-2447.
30. Booth CM, Mackillop W. Translating new medical therapies into societal
benefit: the role of population-based outcome studies. *JAMA*. 2008;300:
2177-2179.
31. Booth CM, Tannock IF. Randomised controlled trials and population-based
observational research: partners in the evolution of medical evidence. *Br J
Cancer*. 2014;110:551-555.
32. Booth C, Tannock I. Evaluation of treatment benefit: randomized controled
trials and population-based observational research. *J Clin Oncol*. 2013;31:
3298-3299.
33. Ang K, Harris J, Wheeler R, et al. Human papillomavirus and survival of
patients with oropharyngeal cancer. *N Engl J Med*. 2010;363:24-35.

---

**How to cite this article:** Hall SF, Griffiths RJ, O'Sullivan BO, Liu F-F. The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. *Head & Neck*. 2019;41:2271–2276. https://doi.org/10.1002/hed.25679